retatrutide ly3437943 triple agonist glp-1 gip glucagon 40mg LY3437943, a novel triple glucagon,

Some Medicare patients will be able to access GLP-1 medication for weight loss for the first time starting July 1, paying a $50 monthly copay through a new program designed to make the drugs more...

Even more concerning

The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).

Additionally, the nominal group technique was used to gather insights from medical experts from different areas regarding the combined therapys daily clinical use, concerns, and limitations

The product also includes BCAAs, which not only support muscle endurance but also contribute to a healthier gut environment by supporting digestive health

This is where wellness starts to collide with pharma